The European Medicines Agency (EMA) will give further details of its restructuring, including its new leadership team at divisional level, in mid-September, the agency has announced. Europe’s top drug regulator first said in May 2013 that it would undergo a major revamp but few details have emerged since then about what the changes actually will mean for the agency and for the pharmaceutical industry.
With completion expected in 2014, there is hope the changes will ease the regulatory burden on companies. Some of the...